New study warns that Trump-era cuts to federal research could jeopardize cancer drug development

A recent study examines how recent political moves to curtail federally funded research could affect cancer drug development.

The analysis notes that over the past decade biopharma companies have become the primary drivers of clinical trial design, reducing the government's influence on research priorities.

The study warns that further reductions in federal funding or oversight, as advocated by the current administration, may limit early-stage discoveries and increase reliance on industry-sponsored trials.

Stakeholders in the pharmaceutical sector are urged to consider the potential slowdown in pipeline innovation and the broader impact on patient access to new therapies.